22.03.2023
Until now, Beijing had not authorized the use in its mainland of this type of preparation developed abroad, such as those from Pfizer-BioNTech and Moderna.
The Chinese pharmaceutical company CSPC Pharmaceutical Group Ltd, announced this Wednesday (03.22.2023) that its vaccine Messenger RNA against covid-19 has received approval from the Chinese authorities for emergency use, becoming the first of its kind authorized in the Asian country.
The company informed the Hong Kong Stock Exchange, where it is listed, that the National Health Commission and the National Administration of Medical Products of the Asian giant gave the green light to its vaccine, called SYS6006. According to the company, a clinical study was carried out between December 10, 2022 and January 18, 2023, in which a protection of 70.2 percent was observed between the seventh and 28th day after immunization and 85, 3% between the 14th and 28th day.
The study analyzed 4,000 cases of immunizations performed with SYS6006, in which “the incidence of adverse effects was relatively low and their severity mild.”
The vaccination campaign in China continental has been based on vaccines produced by the national companies Sinovac, Sinopharm and CanSino, which use inactivated vectors of the virus, one of the most traditional and safe vaccine platforms that exist but whose efficacy is less than that of those based on messenger RNAvaccines that until now had been rejected by China, a decision that has earned the Asian country criticism from international experts.
On January 8, the authorities reduced from category A – level of maximum danger – to Bfor the management of covid-19, thus marking the end of the ‘zero covid’ policy. The removal of restrictions was followed by a surge of infections across the countryduring which moments of great hospital pressure were recorded.
mn (efe, afp)